Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatrist.com
Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.
Psychiatric Pharmacy (BCPP) July 31st 2026
Renal & Urology News
A randomized noninferiority trial involving 648 men with MRI-visible prostate lesions found that cognitive fusion biopsy achieved clinically significant prostate cancer detection rates similar to software-based fusion biopsy. Subgroup analyses suggested body mass index may influence the relative performance of each approach.
Oncology, Medical July 29th 2026
Oncology News Central (ONC)
A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.
Hematology/Oncology July 29th 2026
Annals of Internal Medicine
A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.
MDLinx
An observational study associated repeated gabapentin prescribing with higher rates of dementia and mild cognitive impairment, particularly among adults aged 18 to 64 years. Experts emphasized that the findings do not establish causality and should be interpreted cautiously.
Family Medicine/General Practice July 28th 2026
Medical Xpress
A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.
Hematology/Oncology July 28th 2026